A new blood pressure drug targets a hormone pathway no approved pill has hit

The FDA approved baxdrostat, sold as Baxfendy, on 15 May as an add-on treatment for adults whose hypertension isn't adequately controlled on other drugs [s1] [s2]. It is a first-in-class mechanism for an approved hypertension pill in the U.S.: an aldosterone synthase inhibitor, which blocks the enzyme that makes aldosterone rather than blocking the hormone's receptor after it's already been produced [s1].

Why the mechanism is different

Aldosterone raises blood pressure by prompting the kidneys to retain sodium and water, which increases blood volume; it can also independently drive vascular dysfunction, inflammation and fibrosis [s1]. Existing drugs that target this pathway — spironolactone and eplerenone, for instance — work by blocking the mineralocorticoid receptor that aldosterone binds to, after the hormone is already circulating. Baxdrostat instead inhibits aldosterone synthase, the enzyme responsible for producing aldosterone in the first place, reducing plasma aldosterone concentrations directly [s1]. In clinical trials, baxdrostat lowered aldosterone by up to roughly 70-83% after an initial dose, depending on dietary salt intake, with reductions persisting through the last assessed timepoint at 32 weeks in hypertensive patients [s1].

The label notes baxdrostat has higher potency and selectivity for aldosterone synthase than for the closely related enzyme that produces cortisol, and that it did not affect cortisol responses across a wide dose range in nonclinical and clinical studies — a distinction that matters because a less selective drug could disrupt cortisol production and cause separate hormonal side effects [s1].

What the pivotal trial showed

The approval rests on BaxHTN, a Phase 3 trial in adults with systolic blood pressure between 140 and 170 mmHg who were already taking at least two antihypertensive medications, including a diuretic [s1]. After a placebo run-in period, 794 patients were randomized equally to baxdrostat 1 mg, baxdrostat 2 mg, or placebo, added on top of their existing regimen, for a 12-week double-blind period [s1]. Patients had a mean age of 61, a mean BMI of 31, and substantial existing cardiovascular burden: 37% had type 2 diabetes, 6% had heart failure, and roughly 41% were already on three background antihypertensive medications [s1].

At Week 12, the 2 mg dose reduced systolic blood pressure by a mean of 15.7 mmHg from a baseline of 149.1 mmHg, versus 5.8 mmHg on placebo — a placebo-adjusted difference of 9.8 mmHg (95% CI: 7.0 to 12.6; p<0.0001) [s1]. The 1 mg dose produced a similar effect: a placebo-adjusted difference of 8.7 mmHg (95% CI: 5.8 to 11.5; p<0.0001) [s1]. Diastolic blood pressure improved similarly on both doses [s1]. A later randomized-withdrawal phase of the trial — in which some patients on the 2 mg dose were switched back to placebo — showed blood pressure drifting back up in the withdrawal group while it stayed controlled in patients who continued baxdrostat, a design meant to confirm the effect was attributable to the drug rather than to regression toward the mean [s1].

The tradeoff built into the mechanism

Directly suppressing aldosterone production carries a predictable cost: aldosterone's normal job is regulating potassium and sodium balance, so blocking its synthesis raises the risk of disrupting both. Hyperkalemia — elevated blood potassium — was the most common adverse reaction, occurring in 10.2% of patients on the 2 mg dose and 6.6% on the 1 mg dose, compared with 2.5% on placebo [s1]. It led to permanent discontinuation in 1.8% of 2 mg patients and 0.6% of 1 mg patients, versus none on placebo [s1]. Hyponatremia — low blood sodium — occurred in 3.2% of 2 mg patients and 2.1% of 1 mg patients, versus 0.9% on placebo [s1]. Both risks rose further with age: among patients 75 and older, hyperkalemia occurred in 21% of those on the 2 mg dose, versus none on placebo in that age group [s1]. The label carries no contraindications, but it requires assessing serum potassium and sodium before starting the drug and monitoring both periodically during treatment, with more frequent checks recommended for patients 65 and older, or with diabetes or chronic kidney disease [s1].

A separate, unexplained finding: at Week 12, baxdrostat-treated patients showed a placebo-corrected decrease in estimated kidney filtration rate (eGFR) of roughly 7 to 8 mL/min/1.73m², a reduction that appeared to plateau by Week 12 and reversed after the drug was stopped — a pattern the label attributes to a hemodynamic effect on the kidney rather than structural kidney damage, though it means the drug has not been studied for initiation in patients with eGFR under 45 mL/min/1.73m² [s1].

What is not yet established

The trial measured blood pressure reduction, not cardiovascular outcomes. The label states plainly: "There are no controlled trials demonstrating risk reduction of these events with BAXFENDY," referring to strokes and heart attacks, even though it also notes that blood pressure reduction generally, across many drug classes, has been shown to lower those risks [s1]. Whether baxdrostat's specific mechanism translates that established relationship into fewer strokes and heart attacks for the patients who take it has not itself been directly tested.

What to watch

Whether baxdrostat finds use specifically in patients with treatment-resistant hypertension — those already failing multiple drug classes, the population BaxHTN enrolled — versus broader use earlier in treatment. And whether postmarketing surveillance turns up a hyperkalemia or hyponatremia signal larger than the 12-week trial data suggest, given that long-term uncontrolled follow-up data cited in the label, covering a mean of roughly 9 to 11 months of exposure, describe safety as "consistent" with the short-term trial period rather than presenting new long-term-specific results [s1].

Sources

• [s1] U.S. Food and Drug Administration / AstraZeneca Pharmaceuticals LP, BAXFENDY (baxdrostat) full prescribing information, revised May 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf
• [s2] U.S. Food and Drug Administration, "Novel Drug Approvals for 2026." https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026